Adverse events: race, inequality, and the testing of new pharmaceuticals
Explores the social inequality of clinical drug testing and its effects on scientific resultsImagine that you volunteer for the clinical trial of an experimental drug. The only direct benefit of participating is that you will receive up to
Gespeichert in:
| 1. Verfasser: | |
|---|---|
| Format: | Elektronisch E-Book |
| Sprache: | English |
| Veröffentlicht: |
New York, NY
New York University Press
[2020]
|
| Schriftenreihe: | Anthropologies of American Medicine: Culture, Power, and Practice
|
| Schlagworte: | |
| Online-Zugang: | BSB01 URL des Erstveröffentlichers |
| Zusammenfassung: | Explores the social inequality of clinical drug testing and its effects on scientific resultsImagine that you volunteer for the clinical trial of an experimental drug. The only direct benefit of participating is that you will receive up to |
| Beschreibung: | 1 Online-Ressource (vii, 317 Seiten) Illustrationen |
| ISBN: | 9781479861439 |
Internformat
MARC
| LEADER | 00000nmm a2200000zc 4500 | ||
|---|---|---|---|
| 001 | BV046948296 | ||
| 003 | DE-604 | ||
| 005 | 20210930 | ||
| 007 | cr|uuu---uuuuu | ||
| 008 | 201020s2020 |||| o||u| ||||||eng d | ||
| 020 | |a 9781479861439 |c Online, PDF |9 978-1-4798-6143-9 | ||
| 024 | 7 | |a 10.18574/9781479861439 |2 doi | |
| 035 | |a (ZDB-23-DGG)9781479861439 | ||
| 035 | |a (ZDB-23-SEW)9781479861439 | ||
| 035 | |a (OCoLC)1220888950 | ||
| 035 | |a (DE-599)BVBBV046948296 | ||
| 040 | |a DE-604 |b ger |e rda | ||
| 041 | 0 | |a eng | |
| 049 | |a DE-12 | ||
| 082 | 0 | |a 615.10973 |2 23 | |
| 084 | |a MS 1300 |0 (DE-625)123591: |2 rvk | ||
| 084 | |a MS 3530 |0 (DE-625)123683: |2 rvk | ||
| 084 | |a MS 6220 |0 (DE-625)123745: |2 rvk | ||
| 100 | 1 | |a Fisher, Jill A. |d 1976- |e Verfasser |0 (DE-588)13708434X |4 aut | |
| 245 | 1 | 0 | |a Adverse events |b race, inequality, and the testing of new pharmaceuticals |c Jill A. Fisher |
| 264 | 1 | |a New York, NY |b New York University Press |c [2020] | |
| 264 | 4 | |c © 2020 | |
| 300 | |a 1 Online-Ressource (vii, 317 Seiten) |b Illustrationen | ||
| 336 | |b txt |2 rdacontent | ||
| 337 | |b c |2 rdamedia | ||
| 338 | |b cr |2 rdacarrier | ||
| 490 | 0 | |a Anthropologies of American Medicine: Culture, Power, and Practice | |
| 520 | |a Explores the social inequality of clinical drug testing and its effects on scientific resultsImagine that you volunteer for the clinical trial of an experimental drug. The only direct benefit of participating is that you will receive up to | ||
| 650 | 4 | |a United States | |
| 650 | 4 | |a clinic;clinical trial culture;clinical trials;clinics;confinement;consumption;decision making;demographics;drug development;economic interests;economic motivations;economic need;economic risk;epistemology;health-promoting behavior;healthy volunteers;identity;imbricated stigma | |
| 650 | 4 | |a inclusion-exclusion criteria | |
| 650 | 4 | |a informed consent | |
| 650 | 4 | |a methods | |
| 650 | 4 | |a model organism | |
| 650 | 4 | |a opportunism | |
| 650 | 4 | |a participation | |
| 650 | 4 | |a pharmaceutical industry | |
| 650 | 4 | |a phase I clinical trials | |
| 650 | 4 | |a phase I industry | |
| 650 | 4 | |a phase I trials | |
| 650 | 4 | |a phase I. | |
| 650 | 4 | |a profit | |
| 650 | 4 | |a public health | |
| 650 | 4 | |a qualifying | |
| 650 | 4 | |a race | |
| 650 | 4 | |a region | |
| 650 | 4 | |a reputation | |
| 650 | 4 | |a research participation | |
| 650 | 4 | |a research staff | |
| 650 | 4 | |a risk | |
| 650 | 4 | |a screen failure | |
| 650 | 4 | |a serial participation | |
| 650 | 4 | |a social inequalities | |
| 650 | 4 | |a social inequality | |
| 650 | 4 | |a social network | |
| 650 | 4 | |a social world | |
| 650 | 4 | |a study compensation | |
| 650 | 4 | |a validity | |
| 650 | 7 | |a SOCIAL SCIENCE / Anthropology / General |2 bisacsh | |
| 650 | 4 | |a Drugs |x Testing |x Social aspects |z United States | |
| 650 | 4 | |a Equality |x Health aspects |z United States | |
| 650 | 4 | |a Human experimentation in medicine |x Moral and ethical aspects |z United States | |
| 650 | 4 | |a Racism in medicine |z United States | |
| 650 | 0 | 7 | |a Soziale Ungleichheit |0 (DE-588)4055736-4 |2 gnd |9 rswk-swf |
| 650 | 0 | 7 | |a Egalitarismus |0 (DE-588)4151082-3 |2 gnd |9 rswk-swf |
| 650 | 0 | 7 | |a Menschenversuch |0 (DE-588)4038649-1 |2 gnd |9 rswk-swf |
| 650 | 0 | 7 | |a Klinische Prüfung |0 (DE-588)4031192-2 |2 gnd |9 rswk-swf |
| 650 | 0 | 7 | |a Arzneimittelprüfung |0 (DE-588)4128030-1 |2 gnd |9 rswk-swf |
| 650 | 0 | 7 | |a Arzneimittel |0 (DE-588)4003115-9 |2 gnd |9 rswk-swf |
| 651 | 7 | |a USA |0 (DE-588)4078704-7 |2 gnd |9 rswk-swf | |
| 689 | 0 | 0 | |a USA |0 (DE-588)4078704-7 |D g |
| 689 | 0 | 1 | |a Arzneimittel |0 (DE-588)4003115-9 |D s |
| 689 | 0 | 2 | |a Arzneimittelprüfung |0 (DE-588)4128030-1 |D s |
| 689 | 0 | 3 | |a Egalitarismus |0 (DE-588)4151082-3 |D s |
| 689 | 0 | 4 | |a Klinische Prüfung |0 (DE-588)4031192-2 |D s |
| 689 | 0 | 5 | |a Menschenversuch |0 (DE-588)4038649-1 |D s |
| 689 | 0 | 6 | |a Soziale Ungleichheit |0 (DE-588)4055736-4 |D s |
| 689 | 0 | |5 DE-604 | |
| 776 | 0 | 8 | |i Erscheint auch als |n Druck-Ausgabe, Hardcover |z 9781479877997 |
| 776 | 0 | 8 | |i Erscheint auch als |n Druck-Ausgabe, Paperback |z 9781479862160 |
| 856 | 4 | 0 | |u https://www.degruyter.com/isbn/9781479861439 |x Verlag |z URL des Erstveröffentlichers |3 Volltext |
| 912 | |a ZDB-23-DGG |a ZDB-23-SEW | ||
| 940 | 1 | |q ZDB-23-SEW20 | |
| 999 | |a oai:aleph.bib-bvb.de:BVB01-032356851 | ||
| 966 | e | |u https://www.degruyter.com/isbn/9781479861439 |l BSB01 |p ZDB-23-SEW |q BSB_SEW_NewYorkUniversityPress |x Verlag |3 Volltext | |
Datensatz im Suchindex
| _version_ | 1804181857676296192 |
|---|---|
| adam_txt | |
| any_adam_object | |
| any_adam_object_boolean | |
| author | Fisher, Jill A. 1976- |
| author_GND | (DE-588)13708434X |
| author_facet | Fisher, Jill A. 1976- |
| author_role | aut |
| author_sort | Fisher, Jill A. 1976- |
| author_variant | j a f ja jaf |
| building | Verbundindex |
| bvnumber | BV046948296 |
| classification_rvk | MS 1300 MS 3530 MS 6220 |
| collection | ZDB-23-DGG ZDB-23-SEW |
| ctrlnum | (ZDB-23-DGG)9781479861439 (ZDB-23-SEW)9781479861439 (OCoLC)1220888950 (DE-599)BVBBV046948296 |
| dewey-full | 615.10973 |
| dewey-hundreds | 600 - Technology (Applied sciences) |
| dewey-ones | 615 - Pharmacology and therapeutics |
| dewey-raw | 615.10973 |
| dewey-search | 615.10973 |
| dewey-sort | 3615.10973 |
| dewey-tens | 610 - Medicine and health |
| discipline | Soziologie Medizin |
| discipline_str_mv | Soziologie Medizin |
| format | Electronic eBook |
| fullrecord | <?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>04325nmm a2201045zc 4500</leader><controlfield tag="001">BV046948296</controlfield><controlfield tag="003">DE-604</controlfield><controlfield tag="005">20210930 </controlfield><controlfield tag="007">cr|uuu---uuuuu</controlfield><controlfield tag="008">201020s2020 |||| o||u| ||||||eng d</controlfield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">9781479861439</subfield><subfield code="c">Online, PDF</subfield><subfield code="9">978-1-4798-6143-9</subfield></datafield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.18574/9781479861439</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(ZDB-23-DGG)9781479861439</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(ZDB-23-SEW)9781479861439</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(OCoLC)1220888950</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)BVBBV046948296</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-604</subfield><subfield code="b">ger</subfield><subfield code="e">rda</subfield></datafield><datafield tag="041" ind1="0" ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="049" ind1=" " ind2=" "><subfield code="a">DE-12</subfield></datafield><datafield tag="082" ind1="0" ind2=" "><subfield code="a">615.10973</subfield><subfield code="2">23</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">MS 1300</subfield><subfield code="0">(DE-625)123591:</subfield><subfield code="2">rvk</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">MS 3530</subfield><subfield code="0">(DE-625)123683:</subfield><subfield code="2">rvk</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">MS 6220</subfield><subfield code="0">(DE-625)123745:</subfield><subfield code="2">rvk</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Fisher, Jill A.</subfield><subfield code="d">1976-</subfield><subfield code="e">Verfasser</subfield><subfield code="0">(DE-588)13708434X</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Adverse events</subfield><subfield code="b">race, inequality, and the testing of new pharmaceuticals</subfield><subfield code="c">Jill A. Fisher</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="a">New York, NY</subfield><subfield code="b">New York University Press</subfield><subfield code="c">[2020]</subfield></datafield><datafield tag="264" ind1=" " ind2="4"><subfield code="c">© 2020</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">1 Online-Ressource (vii, 317 Seiten)</subfield><subfield code="b">Illustrationen</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="490" ind1="0" ind2=" "><subfield code="a">Anthropologies of American Medicine: Culture, Power, and Practice</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Explores the social inequality of clinical drug testing and its effects on scientific resultsImagine that you volunteer for the clinical trial of an experimental drug. The only direct benefit of participating is that you will receive up to</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">United States</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">clinic;clinical trial culture;clinical trials;clinics;confinement;consumption;decision making;demographics;drug development;economic interests;economic motivations;economic need;economic risk;epistemology;health-promoting behavior;healthy volunteers;identity;imbricated stigma</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">inclusion-exclusion criteria</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">informed consent</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">methods</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">model organism</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">opportunism</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">participation</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">pharmaceutical industry</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">phase I clinical trials</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">phase I industry</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">phase I trials</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">phase I.</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">profit</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">public health</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">qualifying</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">race</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">region</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">reputation</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">research participation</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">research staff</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">risk</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">screen failure</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">serial participation</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">social inequalities</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">social inequality</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">social network</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">social world</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">study compensation</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">validity</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">SOCIAL SCIENCE / Anthropology / General</subfield><subfield code="2">bisacsh</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Drugs</subfield><subfield code="x">Testing</subfield><subfield code="x">Social aspects</subfield><subfield code="z">United States</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Equality</subfield><subfield code="x">Health aspects</subfield><subfield code="z">United States</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Human experimentation in medicine</subfield><subfield code="x">Moral and ethical aspects</subfield><subfield code="z">United States</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Racism in medicine</subfield><subfield code="z">United States</subfield></datafield><datafield tag="650" ind1="0" ind2="7"><subfield code="a">Soziale Ungleichheit</subfield><subfield code="0">(DE-588)4055736-4</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="650" ind1="0" ind2="7"><subfield code="a">Egalitarismus</subfield><subfield code="0">(DE-588)4151082-3</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="650" ind1="0" ind2="7"><subfield code="a">Menschenversuch</subfield><subfield code="0">(DE-588)4038649-1</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="650" ind1="0" ind2="7"><subfield code="a">Klinische Prüfung</subfield><subfield code="0">(DE-588)4031192-2</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="650" ind1="0" ind2="7"><subfield code="a">Arzneimittelprüfung</subfield><subfield code="0">(DE-588)4128030-1</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="650" ind1="0" ind2="7"><subfield code="a">Arzneimittel</subfield><subfield code="0">(DE-588)4003115-9</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="651" ind1=" " ind2="7"><subfield code="a">USA</subfield><subfield code="0">(DE-588)4078704-7</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="689" ind1="0" ind2="0"><subfield code="a">USA</subfield><subfield code="0">(DE-588)4078704-7</subfield><subfield code="D">g</subfield></datafield><datafield tag="689" ind1="0" ind2="1"><subfield code="a">Arzneimittel</subfield><subfield code="0">(DE-588)4003115-9</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="0" ind2="2"><subfield code="a">Arzneimittelprüfung</subfield><subfield code="0">(DE-588)4128030-1</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="0" ind2="3"><subfield code="a">Egalitarismus</subfield><subfield code="0">(DE-588)4151082-3</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="0" ind2="4"><subfield code="a">Klinische Prüfung</subfield><subfield code="0">(DE-588)4031192-2</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="0" ind2="5"><subfield code="a">Menschenversuch</subfield><subfield code="0">(DE-588)4038649-1</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="0" ind2="6"><subfield code="a">Soziale Ungleichheit</subfield><subfield code="0">(DE-588)4055736-4</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="0" ind2=" "><subfield code="5">DE-604</subfield></datafield><datafield tag="776" ind1="0" ind2="8"><subfield code="i">Erscheint auch als</subfield><subfield code="n">Druck-Ausgabe, Hardcover</subfield><subfield code="z">9781479877997</subfield></datafield><datafield tag="776" ind1="0" ind2="8"><subfield code="i">Erscheint auch als</subfield><subfield code="n">Druck-Ausgabe, Paperback</subfield><subfield code="z">9781479862160</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://www.degruyter.com/isbn/9781479861439</subfield><subfield code="x">Verlag</subfield><subfield code="z">URL des Erstveröffentlichers</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">ZDB-23-DGG</subfield><subfield code="a">ZDB-23-SEW</subfield></datafield><datafield tag="940" ind1="1" ind2=" "><subfield code="q">ZDB-23-SEW20</subfield></datafield><datafield tag="999" ind1=" " ind2=" "><subfield code="a">oai:aleph.bib-bvb.de:BVB01-032356851</subfield></datafield><datafield tag="966" ind1="e" ind2=" "><subfield code="u">https://www.degruyter.com/isbn/9781479861439</subfield><subfield code="l">BSB01</subfield><subfield code="p">ZDB-23-SEW</subfield><subfield code="q">BSB_SEW_NewYorkUniversityPress</subfield><subfield code="x">Verlag</subfield><subfield code="3">Volltext</subfield></datafield></record></collection> |
| geographic | USA (DE-588)4078704-7 gnd |
| geographic_facet | USA |
| id | DE-604.BV046948296 |
| illustrated | Not Illustrated |
| index_date | 2024-07-03T15:40:23Z |
| indexdate | 2024-07-10T08:58:19Z |
| institution | BVB |
| isbn | 9781479861439 |
| language | English |
| oai_aleph_id | oai:aleph.bib-bvb.de:BVB01-032356851 |
| oclc_num | 1220888950 |
| open_access_boolean | |
| owner | DE-12 |
| owner_facet | DE-12 |
| physical | 1 Online-Ressource (vii, 317 Seiten) Illustrationen |
| psigel | ZDB-23-DGG ZDB-23-SEW ZDB-23-SEW20 ZDB-23-SEW BSB_SEW_NewYorkUniversityPress |
| publishDate | 2020 |
| publishDateSearch | 2020 |
| publishDateSort | 2020 |
| publisher | New York University Press |
| record_format | marc |
| series2 | Anthropologies of American Medicine: Culture, Power, and Practice |
| spelling | Fisher, Jill A. 1976- Verfasser (DE-588)13708434X aut Adverse events race, inequality, and the testing of new pharmaceuticals Jill A. Fisher New York, NY New York University Press [2020] © 2020 1 Online-Ressource (vii, 317 Seiten) Illustrationen txt rdacontent c rdamedia cr rdacarrier Anthropologies of American Medicine: Culture, Power, and Practice Explores the social inequality of clinical drug testing and its effects on scientific resultsImagine that you volunteer for the clinical trial of an experimental drug. The only direct benefit of participating is that you will receive up to United States clinic;clinical trial culture;clinical trials;clinics;confinement;consumption;decision making;demographics;drug development;economic interests;economic motivations;economic need;economic risk;epistemology;health-promoting behavior;healthy volunteers;identity;imbricated stigma inclusion-exclusion criteria informed consent methods model organism opportunism participation pharmaceutical industry phase I clinical trials phase I industry phase I trials phase I. profit public health qualifying race region reputation research participation research staff risk screen failure serial participation social inequalities social inequality social network social world study compensation validity SOCIAL SCIENCE / Anthropology / General bisacsh Drugs Testing Social aspects United States Equality Health aspects United States Human experimentation in medicine Moral and ethical aspects United States Racism in medicine United States Soziale Ungleichheit (DE-588)4055736-4 gnd rswk-swf Egalitarismus (DE-588)4151082-3 gnd rswk-swf Menschenversuch (DE-588)4038649-1 gnd rswk-swf Klinische Prüfung (DE-588)4031192-2 gnd rswk-swf Arzneimittelprüfung (DE-588)4128030-1 gnd rswk-swf Arzneimittel (DE-588)4003115-9 gnd rswk-swf USA (DE-588)4078704-7 gnd rswk-swf USA (DE-588)4078704-7 g Arzneimittel (DE-588)4003115-9 s Arzneimittelprüfung (DE-588)4128030-1 s Egalitarismus (DE-588)4151082-3 s Klinische Prüfung (DE-588)4031192-2 s Menschenversuch (DE-588)4038649-1 s Soziale Ungleichheit (DE-588)4055736-4 s DE-604 Erscheint auch als Druck-Ausgabe, Hardcover 9781479877997 Erscheint auch als Druck-Ausgabe, Paperback 9781479862160 https://www.degruyter.com/isbn/9781479861439 Verlag URL des Erstveröffentlichers Volltext |
| spellingShingle | Fisher, Jill A. 1976- Adverse events race, inequality, and the testing of new pharmaceuticals United States clinic;clinical trial culture;clinical trials;clinics;confinement;consumption;decision making;demographics;drug development;economic interests;economic motivations;economic need;economic risk;epistemology;health-promoting behavior;healthy volunteers;identity;imbricated stigma inclusion-exclusion criteria informed consent methods model organism opportunism participation pharmaceutical industry phase I clinical trials phase I industry phase I trials phase I. profit public health qualifying race region reputation research participation research staff risk screen failure serial participation social inequalities social inequality social network social world study compensation validity SOCIAL SCIENCE / Anthropology / General bisacsh Drugs Testing Social aspects United States Equality Health aspects United States Human experimentation in medicine Moral and ethical aspects United States Racism in medicine United States Soziale Ungleichheit (DE-588)4055736-4 gnd Egalitarismus (DE-588)4151082-3 gnd Menschenversuch (DE-588)4038649-1 gnd Klinische Prüfung (DE-588)4031192-2 gnd Arzneimittelprüfung (DE-588)4128030-1 gnd Arzneimittel (DE-588)4003115-9 gnd |
| subject_GND | (DE-588)4055736-4 (DE-588)4151082-3 (DE-588)4038649-1 (DE-588)4031192-2 (DE-588)4128030-1 (DE-588)4003115-9 (DE-588)4078704-7 |
| title | Adverse events race, inequality, and the testing of new pharmaceuticals |
| title_auth | Adverse events race, inequality, and the testing of new pharmaceuticals |
| title_exact_search | Adverse events race, inequality, and the testing of new pharmaceuticals |
| title_exact_search_txtP | Adverse events race, inequality, and the testing of new pharmaceuticals |
| title_full | Adverse events race, inequality, and the testing of new pharmaceuticals Jill A. Fisher |
| title_fullStr | Adverse events race, inequality, and the testing of new pharmaceuticals Jill A. Fisher |
| title_full_unstemmed | Adverse events race, inequality, and the testing of new pharmaceuticals Jill A. Fisher |
| title_short | Adverse events |
| title_sort | adverse events race inequality and the testing of new pharmaceuticals |
| title_sub | race, inequality, and the testing of new pharmaceuticals |
| topic | United States clinic;clinical trial culture;clinical trials;clinics;confinement;consumption;decision making;demographics;drug development;economic interests;economic motivations;economic need;economic risk;epistemology;health-promoting behavior;healthy volunteers;identity;imbricated stigma inclusion-exclusion criteria informed consent methods model organism opportunism participation pharmaceutical industry phase I clinical trials phase I industry phase I trials phase I. profit public health qualifying race region reputation research participation research staff risk screen failure serial participation social inequalities social inequality social network social world study compensation validity SOCIAL SCIENCE / Anthropology / General bisacsh Drugs Testing Social aspects United States Equality Health aspects United States Human experimentation in medicine Moral and ethical aspects United States Racism in medicine United States Soziale Ungleichheit (DE-588)4055736-4 gnd Egalitarismus (DE-588)4151082-3 gnd Menschenversuch (DE-588)4038649-1 gnd Klinische Prüfung (DE-588)4031192-2 gnd Arzneimittelprüfung (DE-588)4128030-1 gnd Arzneimittel (DE-588)4003115-9 gnd |
| topic_facet | United States clinic;clinical trial culture;clinical trials;clinics;confinement;consumption;decision making;demographics;drug development;economic interests;economic motivations;economic need;economic risk;epistemology;health-promoting behavior;healthy volunteers;identity;imbricated stigma inclusion-exclusion criteria informed consent methods model organism opportunism participation pharmaceutical industry phase I clinical trials phase I industry phase I trials phase I. profit public health qualifying race region reputation research participation research staff risk screen failure serial participation social inequalities social inequality social network social world study compensation validity SOCIAL SCIENCE / Anthropology / General Drugs Testing Social aspects United States Equality Health aspects United States Human experimentation in medicine Moral and ethical aspects United States Racism in medicine United States Soziale Ungleichheit Egalitarismus Menschenversuch Klinische Prüfung Arzneimittelprüfung Arzneimittel USA |
| url | https://www.degruyter.com/isbn/9781479861439 |
| work_keys_str_mv | AT fisherjilla adverseeventsraceinequalityandthetestingofnewpharmaceuticals |